Phaseline

Companies › BioMarin Pharmaceutical

BioMarin Pharmaceutical: clinical trials, targets and expected readouts

9 active drug programs in 18 registered trials: 8 Phase 2, 4 Phase 3, 4 Phase 1, 2 Phase 4; Metabolic and endocrine, Other, Hematology, Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pegvaliase
Phenylalanine ammonia-lyase (PAL) enzyme - degrades phenylalanine to ammonia and trans-cin
PAHPhase 4Phenylketonuria; Phenylketonuria (PKU)Sep 2027
Palynziq
Pegvaliase (PEGylated recombinant phenylalanine ammonia-lyase)
PAHPhase 4Phenylketonuria–
Vosoritide
Atrial natriuretic peptide receptor B binding agent
NPR2Phase 3Hypochondroplasia; Achondroplasia; Noonan Syndrome; Idiopathic Short Stature …Mar 2027
valoctocogene roxaparvovec
Coagulation factor IX exogenous protein
F9Phase 3Hemophilia AMar 2029
BMN 333
C-type natriuretic peptide (CNP) receptor agonist
–Phase 2AchondroplasiaJun 2029
BMN 351
Antisense oligonucleotide targeting DMD exon 51
–Phase 1Duchenne Muscular DystrophyApr 2027
BMN 307
AAV gene therapy delivering phenylalanine hydroxylase (PAH) gene
PAHPhase 1Phenylketonuria (PKU)Dec 2027
BMN 331
AAV5-based gene therapy expressing wild-type human C1 Esterase Inhibitor (hC1-INH)
–Phase 1Hereditary AngioedemaNov 2028
BMN 349–Phase 1Alpha 1-Antitrypsin Deficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06455059VosoritidePhase 3HypochondroplasiaOtherAug 2026
NCT06780332PalynziqPhase 4PhenylketonuriaMetabolic and endocrineAug 2026
NCT06738017BMN 349Phase 1Alpha 1-Antitrypsin DeficiencyMetabolic and endocrineAug 2026
NCT06668805VosoritidePhase 2Noonan SyndromeOtherMar 2027
NCT06280209BMN 351Phase 1Duchenne Muscular DystrophyNeurologyApr 2027
NCT07477691PegvaliasePhase 4PhenylketonuriaMetabolic and endocrineSep 2027
NCT05270837PegvaliasePhase 3Phenylketonuria (PKU)Metabolic and endocrineOct 2027
NCT04554940VosoritidePhase 2AchondroplasiaOtherDec 2027
NCT02724228VosoritidePhase 2AchondroplasiaOtherDec 2027
NCT04480567BMN 307Phase 1Phenylketonuria (PKU)Metabolic and endocrineDec 2027
NCT07126262VosoritidePhase 2HypochondroplasiaOtherJun 2028
NCT05121376BMN 331Phase 1Hereditary AngioedemaImmunologyNov 2028
NCT06224907valoctocogene roxaparvovecPhase 3Hemophilia AHematologyMar 2029
NCT07441876BMN 333Phase 2AchondroplasiaOtherJun 2029
NCT03424018VosoritidePhase 3AchondroplasiaOtherJun 2031
NCT04219007VosoritidePhase 2Short StatureMetabolic and endocrineJun 2035
NCT06382155VosoritidePhase 2Idiopathic Short StatureMetabolic and endocrineDec 2036
NCT03989947VosoritidePhase 2AchondroplasiaOtherMay 2038

From the company's SEC filings

Cash and short-term investments of $736m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PAH (3) F9 (1) NPR2 (1)

Companies with the same targets

CSL Behring PTC Therapeutics Chongqing Peg-Bio Biopharm NGGT Agios Pharmaceuticals NGGT (Suzhou) Biotechnology Pfizer Roche Shanghai Xinzhi BioMed IntraBio

Companies built like this

PTC Therapeutics Viking Therapeutics CSPC Ouyi Pharmaceutical Amylyx Pharmaceuticals Rhythm Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.